TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+32.01%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$288M
AUM Growth
+$288M
(+42%)
Cap. Flow
+$54.3M
Cap. Flow
% of AUM
18.81%
Top 10 Holdings %
Top 10 Hldgs %
62.41%
Holding
37
New
13
Increased
8
Reduced
6
Closed
9
Top Buys
| 1 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$19.9M |
| 2 |
Merck
MRK
|
$15.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$14.9M |
| 4 |
Baxter International
BAX
|
$13.6M |
| 5 |
Merus
MRUS
|
$12.9M |
Top Sells
| 1 |
AbbVie
ABBV
|
$26M |
| 2 |
GE HealthCare
GEHC
|
$13.3M |
| 3 |
Biogen
BIIB
|
$11.9M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$11.8M |
| 5 |
Praxis Precision Medicines
PRAX
|
$8.68M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Perspective Therapeutics
CATX
$251M
| $929K | 0.32% |
+780,303
| New | +$929K |
|
27
Femasys
FEMY
$12M
| $47.4K | 0.02% |
30,606
-5,544
| -15% | -$8.59K |
|
|
CTLT
28
DELISTED
CATALENT, INC.
CTLT
| – | – |
-261,797
| Closed | -$11.8M |
|
|
VRNA
29
Verona Pharma
VRNA
$9.18B
| – | – |
-293,112
| Closed | -$5.83M |
|
|
30
AbbVie
ABBV
$374B
| – | – |
-167,807
| Closed | -$26M |
|
31
AstraZeneca
AZN
$255B
| – | – |
-58,787
| Closed | -$3.96M |
|
|
32
Biogen
BIIB
$20.8B
| – | – |
-45,814
| Closed | -$11.9M |
|
|
33
GE HealthCare
GEHC
$33B
| – | – |
-171,676
| Closed | -$13.3M |
|
34
Immatics
IMTX
$662M
| – | – |
-275,482
| Closed | -$2.9M |
|
35
Kenvue
KVUE
$39.2B
| – | – |
0
| – | – |
|
36
MoonLake Immunotherapeutics
MLTX
$3.78B
| – | – |
-47,604
| Closed | -$2.87M |
|
37
Scholar Rock
SRRK
$3.3B
| – | – |
-207,147
| Closed | -$3.89M |
|